EMA update on metformin diabetes medicines
EMA is aware that trace amounts of an impurity, N-nitrosodimethylamine (NDMA), have been found in a small number of metformin diabetes medicines outside the EU.
The levels of NDMA in the affected non-EU metformin medicines are very low and appear to be within or even below the range that people can be exposed to from other sources, including certain foods and water.
At this point, there are no data indicating that EU metformin medicines are affected. Authorities in the EU are in the process of working with companies to test EU medicines and will provide further updates as more information becomes available.
Patients in the EU should continue taking their metformin medicines as normal. The risk from not having adequate diabetes treatment far outweighs possible effects of the low levels of NDMA seen in tests. Healthcare professionals should remind patients of the importance of keeping their diabetes under control.
Metformin is widely used alone or in combination with other medicines to treat type 2 diabetes. It is usually the first-line treatment, and it works by reducing the production of glucose in the body and reducing its absorption from the gut.
|Information for patients and healthcare professionals|
Remind your patients of the importance of keeping their diabetes under control.
NDMA is classified as a probable human carcinogen (a substance that could cause cancer) on the basis of animal studies. It is present in some foods and in water supplies, but it is not expected to cause harm when ingested in very low levels.
Last year, NDMA and other impurities of the same class (nitrosamines) were found in some blood pressure medicines known as sartans. Subsequently, EMA started a review of ranitidine medicines and launched a procedure to request companies to take specific measures to avoid the presence of nitrosamines in human medicines, including metformin.
This procedure, known as an Article 5 (3) procedure, is still ongoing and will be used to provide guidance to companies and support the evaluation of data on nitrosamines. The expedited testing of metformin medicines in the EU is part of this procedure.
EMA and national authorities together with international partners and the European Directorate for the Quality of Medicines & HealthCare (EDQM) are continuously sharing information about impurities such as NDMA and are taking action to protect patients and reassure them about the quality of their medicines.